Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Rosen Law Firm Reminds Alcobra Ltd. Investors of Important January 19, 2015 Deadline in Class Action - ADHD

ARCT

NEW YORK, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Rosen Law Firm reminds purchasers of Alcobra Ltd. common stock (Nasdaq:ADHD) during the period from March 28, 2014 through November 14, 2014, of the important January 19, 2015 deadline in the class action.

To join the Alcobra class action, go to the website http://www.rosenlegal.com/cases-448.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY CHOOSE TO DO NOTHING AT THIS POINT AND REMAIN AN ABSENT CLASS MEMBER.

The lawsuit asserts Alcobra misrepresented the results of its Phase 3 clinical trials for its product candidate MDX intended for treating attention deficit hyperactivity disorder. Specifically, the complaint alleges that Alcobra misled investors by misrepresenting or concealing that: (1) MDX did not show a statistically significant benefit over placebo except after it removed certain patients from the Phase 3 study analysis; (2) Alcobra presented its analyses inconsistently, including post hoc analyses outside the original protocols; and (3), as a result Alcobra's statements about the clinical success of MDX, were false and misleading and or lacked a reasonable basis.

The complaint alleges that as a result of Alcobra's misleading statements, its share price has declined, damaging investors.

If you wish to join the class action at no cost go to http://www.rosenlegal.com/cases-448.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

CONTACT: Laurence Rosen, Esq.
         Phillip Kim, Esq.
         Jonathan Horne, Esq.
         The Rosen Law Firm P.A.
         275 Madison Avenue, 34th Floor
         New York, NY 10016
         Tel: (212) 686-1060
         Toll Free: (866) 767-3653
         Fax: (212) 202-3827
         lrosen@rosenlegal.com
         pkim@rosenlegal.com
         jhorne@rosenlegal.com
         www.rosenlegal.com